In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$ 13.28 ...

The technology was announced at the JP Morgan Healthcare Conference in San Francisco. In this project, the stakeholders aim to use a human reference genome to combine with patient data in order to try ...

DNA Sequencing Market Fueled by Genomics Research, Personalized Medicine, and AI-Powered Advancements, the DNA Sequencing <a target=_blank ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

The US company said that results from the Alpha-CORRECT trial saw its colon cancer diagnostic Oncodetect achieving a ...

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients ...

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium ...

Wolff's case was published in the New England Journal of Medicine as an early example of precision cancer treatment. Nearly 10 years later, researchers can sequence a person's entire genome in ...